about
Psoriasis and cardiovascular disorders.Novel sodium hypochlorite cleanser shows clinical response and excellent acceptability in the treatment of atopic dermatitis.PSORS2 is due to mutations in CARD14.A subset of methylated CpG sites differentiate psoriatic from normal skin.Levamisole-induced vasculitis.The use of ustekinumab in autoimmune disease.The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis.The use of cyclosporine in dermatology: part I.The use of cyclosporine in dermatology: part II.Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.Current investigational drugs in psoriasis.Research gaps in psoriasis: opportunities for future studies.Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.An overview of developing TNF-α targeted therapy for the treatment of psoriasis.From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.Ponesimod--a future oral therapy for psoriasis?Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.Disseminated cutaneous histoplasmosis in newly diagnosed HIV.Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes.Complete skin examination is essential in the assessment of dermatology patients: findings from 483 patients.Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials.Clinical and genetic predictors of response to narrowband ultraviolet B for the treatment of chronic plaque psoriasis.The effect of narrowband UV-B treatment for psoriasis on vitamin D status during wintertime in Ireland.The prevalence of Dupuytren contractures in patients with psoriasis.Patients' Perspectives on the Impact of Genital Psoriasis: A Qualitative Study.Infection-free Clinical Response Among Patients With Hidradenitis Suppurativa Who Were Treated With Adalimumab: Results from Two Phase 3 Studies.Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.Genital psoriasis is associated with significant impairment in quality of life and sexual functioning.Identification of pharmacogenetic markers of treatment response to biologic therapies in psoriasis - is there a benefit?Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis.Management of psoriasis in patients with inflammatory bowel disease: From the Medical Board of the National Psoriasis Foundation.The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health.The Development of a Patient-Reported Outcome Measure for Assessment of Genital Psoriasis Symptoms: The Genital Psoriasis Symptoms Scale (GPSS).Juvenile folliculotropic and ichthyosiform mycosis fungoides.Discordance between physician assessment of psoriasis and patient self-assessment: the importance of itchThe use of tumor necrosis factor inhibitors in pregnancy: What is the evidence?Flow CytometryPsoriasis and cardiovascular disordersCytomegalovirus-induced cutaneous vasculopathy and perianal ulcerationTreatment of acrodermatitis continua of Hallopeau with adalimumab
P50
Q30245367-CC28CB0E-EF5F-4438-ADC9-55E18D0D28B6Q34341187-E4577499-2EB6-475B-BD32-4EF0116B1714Q34637710-9AE30996-7D9B-4A39-93C0-D0D34996CAE5Q36600085-7EA16B75-6185-4C41-9C94-737D966188BCQ36703137-52F885B5-A998-4D27-92F2-4451EC2E3968Q37706606-00E4D486-3298-4E2C-88B1-C30185DD3CFAQ37722744-357891B8-5634-47F2-BE32-DF83BB14DE55Q37811215-09292BC6-E8C1-42B0-8775-34C905D5762FQ37811216-E1BDA054-A310-44C6-BA41-ED9317882AAAQ37838534-8836E151-4EA9-4013-829E-DC1B1AAA5B3EQ37991748-B10BB20F-8B6E-4B7D-BC67-DF0876BB6793Q38152571-84A0FF35-4EDE-411E-9D4F-5A938DAB73D9Q38269971-A658321C-9A8A-4057-AA51-45A07E5C356AQ38569794-E73DE04B-A94E-4983-9E79-1FC73AED5964Q39026329-71FC4709-4CBE-4ED9-B183-00DCE46E5EADQ39144447-F2963E47-B498-4B88-8497-64892F6ECA0DQ39205065-BFC44566-5FC5-424D-A658-571A5D5852C5Q40124588-EB811A87-FBFC-44EE-A895-2FF7D7853F0EQ40609419-430291DA-E994-4D2F-8ECC-24F0D22A6A65Q42490684-812BB7A8-FE92-4F12-B0AB-72A745596065Q42613896-040EEF8F-EBE1-41AF-85F0-12F6295DC80EQ42935030-11C5A36F-6A77-48C8-B3FA-A8182606AD33Q43860960-DD8F25BC-7EA7-4BC4-9C71-A20E6856F1C9Q44668123-37FA24CD-8CAC-4290-92DC-D4BB4205DA87Q45977006-D3DCF4CD-E81C-45E9-B683-CFBF45D6CD6BQ47428065-5365D074-D719-44C3-8FDF-C49F3105908BQ47812411-D9073C34-9CF5-4DDA-AD1C-5776E1B91A17Q48043071-C089B465-1292-43EB-A8B1-4352D52BAD56Q48145072-E384CECA-F869-45D8-8F8B-BD29685F5182Q49587627-F60B9B35-A9F0-4819-A58D-1491968F8718Q50051873-C7C34FF1-AA36-4B12-9CC2-3CA34426F080Q50075890-90E071DF-4F16-4858-9CD5-B2B6D3101DD4Q50075895-3B768210-335B-41C0-9D7B-33729FC4F71EQ53521306-493FAB03-14D0-474D-AD8A-5FFE9F6EEF55Q60520691-981BA8F1-5092-447E-91FC-06F50F4A2584Q60520697-BDFD7FA4-C206-47E7-91F2-A5BF19E10F67Q60520704-9EC18D3F-ACCC-416C-88C1-66626E4895A6Q60520709-9F1D9286-86F2-4BA3-99B1-641140480A34Q60520731-9BEEE3DE-B14D-4919-84F0-E6F8A400FCA5Q60520757-631031BD-14AC-4A24-9CD1-7E23217278C4
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Caitriona Ryan
@ast
Caitriona Ryan
@en
Caitriona Ryan
@es
Caitriona Ryan
@nl
Caitriona Ryan
@sl
type
label
Caitriona Ryan
@ast
Caitriona Ryan
@en
Caitriona Ryan
@es
Caitriona Ryan
@nl
Caitriona Ryan
@sl
prefLabel
Caitriona Ryan
@ast
Caitriona Ryan
@en
Caitriona Ryan
@es
Caitriona Ryan
@nl
Caitriona Ryan
@sl
P106
P108
P21
P31
P496
0000-0003-1915-546X